SBIR/STTR Research Award

Hematological Diagnosis of B Thalassemia Mutations

Award identifier ba539737f36abe3bd898f65dd4fe0568c9c2f2bc354d6847a2f8e5680bbd1113Awarding agency Department of Health and Human Services

Award amount

$50,000

Program and phase

SBIR · Phase I

Award year

1993

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Not reported
Recipient company
Chi Associates, Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

Beta thalassemia, the most common disease inherited at a single genetic locus, is a major cause of morbidity and mortality in populations having high frequencies of the beta-thalassemia mutations. At this juncture, the mainstays of therapy in afflicted populations consist of population screening, genetic counseling, and prenatal diagnosis. Accurate diagnosis, on which each of these depends, entails detecting at the DNA level beta-thalassemia mutations, which are both numerous and of diverse ethnic distribution. Practical diagnosis of beta-thalassemia mutation in distinct ethnic groups requires both accuracy and a level of simplicity that can be applied outside dedicated research laboratories. We will use the polymerase chain reaction (PCR)-based Reverse Dot Blot method to develop diagnostic kits for the beta-thalassemia mutations found commonly in Southeast Asian and in African-American populations. The Reverse Dot Blot method is sensitive because it employs PCR to amplify 100,000 to 1,000,000 times the genes to be tested, accurate because it depends on the same Watson- Crick base pairing that insures faithful transmission of genes from one generation to the next, and efficient because it tests amplified gene target sequences for the presence of several mutations in a single hybridization reaction. We will design oligonucleotide probes complementary to the beta-thalassemia mutations segregating in defined populations and to their allelic wild-type sequences, fix these probe pairs to filters, amplify and label target DNA to be tested, and determine if the test DNA contains mutant beta-thalassemia sequences by whether it hybridizes to fixed mutant probes or only to wild type probes. Diagnostic kits designed using this method will be applied to the rapid, accurate diagnosis of beta-thalassemia, which will greatly facilitate screening, counseling, and prenatal diagnosis in popula- tions at risk.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.